Stockscreener 앱 받기
0.6651
5.91%
0.0371
시간 외 거래:
.66
-0.0051
-0.77%
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - jammulinksnews.com
What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - jammulinksnews.com
How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - jammulinksnews.com
Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - jammulinksnews.com
What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - jammulinksnews.com
What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - jammulinksnews.com
What catalysts could drive Moleculin Biotech Inc. stock higher in 2025Robust financial gains - jammulinksnews.com
How volatile is Moleculin Biotech Inc. stock compared to the marketFree Stock Market Forecast Reports - jammulinksnews.com
How strong is Moleculin Biotech Inc. company’s balance sheetFree Stock Market Mentorship - jammulinksnews.com
Moleculin Biotech Releases Corporate Presentation Update - The Globe and Mail
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Inc. Ranks High in Smart Money TrackerROI Driven Equity Selection With Safety Emphasized - metal.it
What Caused the Sharp Drop in Moleculin Biotech (MBRX.O)? - AInvest
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin - GlobeNewswire
Will Moleculin Biotech Inc. Stock Benefit from AI and Green Energy TrendsAccurate Buy Point for Momentum Stocks Detected - metal.it
Moleculin receives European patent notice for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin receives European patent notice for cancer drug Annamycin - Investing.com
Moleculin Biotech Secures European Patent for Annamycin - TipRanks
Moleculin Biotech, Inc. Receives Notice of Intent to Grant European Patent for Annamycin, Strengthening Market Position in Oncology - Quiver Quantitative
Breakthrough Cancer Drug Patent: Moleculin's Non-Cardiotoxic Treatment Gains EU Protection Until 2040 - Stock Titan
Why Did Moleculin Biotech Inc. (MBRX) Soar 10.08%? - AInvest
Statistical indicators supporting Moleculin Biotech Inc.’s strengthIntraday Trend Analysis for Fast Gains Released - metal.it
Why Did Moleculin Biotech Inc. (MBRX) Soar 11.82%? - AInvest
why MBRX is up afterhours - AInvest
Why Moleculin Biotech Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What are analysts’ price targets for Moleculin Biotech Inc. in the next 12 monthsConsistently exceptional gains - jammulinksnews.com
When is Moleculin Biotech Inc. stock expected to show significant growthAchieve breakthrough gains with smart trades - jammulinksnews.com
whats better mbrx or pstv - AInvest
How high can Moleculin Biotech Inc. stock price go in 2025High-margin investment plays - jammulinksnews.com
Moleculin Biotech Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
What drives Moleculin Biotech Inc. stock priceUnprecedented market success - PrintWeekIndia
What analysts say about Moleculin Biotech Inc. stockFree Risk Assessment Services - jammulinksnews.com
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan
0.93%
0.15%
자본화:
|
볼륨(24시간):